Elevated International Normalized Ratio associated with concurrent use of sorafenib and warfarin

American Journal of Health-System Pharmacy

Volumn 66, Issue 23, 2009, Pages 2123-2125

  Moretti, Laura V ^a   Montalvo, Rolf O ^b  

^a HARRIS COUNTY HOSPITAL DISTRICT   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Anticoagulants; Antineoplastic agents; Drug interactions; Geriatrics; Hemorrhage; International normalized ratio; Liver neoplasms; Sorafenib; Toxicity; Warfarin

Indexed keywords

SORAFENIB; WARFARIN;

AGED; ANAMNESIS; ARTICLE; BLEEDING; CASE REPORT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONGESTIVE HEART FAILURE; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; GASTROESOPHAGEAL REFLUX; HEART ATRIUM FIBRILLATION; HEPATITIS C; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY FUNCTION; LABORATORY TEST; LEG BLEEDING; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; PROTHROMBIN TIME;

EID: 73649094145     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp080436     Document Type: Article

References (10)

1. Singer DE, Albers GW, Dalen JE et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008; 133(suppl 6):546S-592S.
2. Nexavar (sorafenib) package insert. West Haven, CT: Bayer Pharmaceuticals; 2005 Dec.
3. Dipiro JT, Talbert RL, Yee GC et al. Pharmacotherapy: a pathophysiologic approach. 5th ed. Columbus, OH: McGraw Hill; 2002.
4. Clinical Pharmacology. Sorafenib and warfarin drug monographs. www.clinicalpharmacology.com/ (accessed 2008 Jun 4).
5. LEXI-COMP Online. Warfarin and sorafenib drug monographs. http://online.lexi.com/crlsql/servlet/crlonline (accessed 2008 Jun 4).
6. Micromedex. Sorafenib and warfarin drug monographs. www.micromedex.com/ (accessed 2008 Jun 4).
7. Kamba T, MacDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007; 96:1788-1795 (Pubitemid 46912024)
8. Kilickap S, Abali H, Celik I. Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol. 2003; 21:3542. Letter.
9. Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30:239-245
10. Horn J, Hanston P, Chan L. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother. 2007; 41:674-80.